Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4451 The management of well-differentiated gastroenteropancreatic neuroendocrine tumours in a tertiary centre – The contribution of radionuclide therapy

Introduction: Neuroendocrine tumours represent a heterogenous group of tumours with different locations, whose management is necessary to identify specific parameters that determine the choice of optimal treatment.

Conference:

Presenting Author: Oana Stefania S

Authors: Oana Stefania S, Corin B, Victoria V, Sofia L,

Keywords: GEP-NET, well-differentiated, PRRT, Cromogranine A, Serotonin, RECIST 1.1,

#3142 Patient-reported cognitive and psychological screening in neuroendocrine tumors (NETs): A prospective cohort study

Introduction: An association between neuroendocrine tumors (NET) and neuropsychological symptoms has been suggested, but objective data is limited.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Hallet J

Authors: Hallet J, Law C, Kazdan J, Zuk V, Singh S,

Keywords: neuroendocrine, patient-reported, cognitive, depression,

#3141 Incidence of psychiatric illness in patients with neuroendocrine tumors (NET): A comparative population-based analysis

Introduction: Diversion of tryptophan to tumoral hormonal production has been suggested to result in increased prevalence of psychiatric illnesses (PI) in neuroendocrine tumors (NET), but such data are limited to case reports.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Hallet J

Authors: Hallet J, Isenberg-Grzeda E, Law C, Zuk V, Sohail S,

Keywords: neuroendocrine, psychiatry, mental health, prognosis,

#1869 Synergistic Effects of Combining Hsp90 and PI3K Inhibitors with Everolimus in Pancreatic Neuroendocrine Tumors

Introduction: The development of the first molecular targeted therapies for neuroendocrine tumors (NET) was a milestone in the treatment of patient. Nevertheless, these therapies eventually fail and patients become resistant to the treatment. One way of escaping this dilemma might be the combination of targeted drugs to prevent resistance development.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Schrader J

Authors: Weissmann V, Benten D, Fahl M, Eggers C, Izbicki J,

Keywords: targeted therapies, mTOR,

#1248 Case Report of Recurrent VIPoma

Introduction: 51yr presented with 7 month diarrhoea&2 stone weight loss. All tests negative, only abnormality hypokalaemia. FGH profile: VIP raised>400, peptide histidine methionine>1000, GAWK of 250. Diagnosis of VIPoma. CT: 5cm mass tail & body of pancreas, no hepatic or adrenal lesions. Octreotide treatment started. Bowel frequency improved, hypokalaemia corrected. Octreotide scan showed uptake only in pancreas. Patient readmitted 5 months later hypokalaemic myopathy, K 1.7, surgical distal pancreatectomy & splenectomy completed. Histology: NET within pancreas, moderate cellular differentiation, variable mitotic rate.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Mulcahy V, McStay M, Sizer B,

Keywords: VIPoma,